Arrhythmias are considered a prominent phenomenon in pulmonary hypertension (PH) as the
disease progresses. According primarily to retrospective studies with up to 24 hours of
monitoring, supraventricular tachycardias (SVT) can be found in 8-35% of patients, with
significant impact on survival.
Furthermore, a few prospective studies to date deploying short-term monitoring (10 minutes-24
hours) have revealed lower heart rate variability (HRV) in patients with pulmonary arterial
In ASPIRE arrhythmias and heart rate variability is being assessed via long term monitoring.
Pulmonary hypertension represents a challenging and heterogeneous condition that is
associated with high mortality and morbidity if left untreated. Artificial intelligence is
used to study and develop theories and methods that simulate and extend human intelligence,
which is being applied in fields related to cardiovascular diseases. The study intends to
combine multimodal clinical data of patients who undergo right heart catheterization at Fuwai
Hospital with artificial intelligence techniques to create programs that can screen and
diagnose pulmonary hypertension.
The study aim is to monitor, during exercise tests carried out in various conditions, the
alveolar dead space, by means of continuous transcutaneous measurement of Pt CO2, which would
be used as a surrogate for arterial PaCO2. Validity of this measurement needs to be assessed
against arterial sampling (either arterial, or arterialized capillary), especially with
regards to the lag time required by the CO2 diffusion from the arterial compartment (PaCO2)
to the cutaneous one (PtCO2), in particular when rapid changes of CO2 might be induced by
The evaluation will be done in 2 different settings:
- intensive care...
This is a prospective pilot study to assess the plasma levels of particular proteins involved
in the transforming growth factor beta (TGF-β) pathway and its down stream regulators, CHIP,
as well as micro RNA molecules in subjects with pulmonary arterial hypertension (PAH) and
compare them to control subjects without PAH to see if they can be used as a diagnostic or
prognostic marker of PAH and how this compares to other diagnostic biomarkers N-terminal
pro-natriuretic peptide (NT Pro-BNP) and C-reactive protein (CRP).
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of
ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or
PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
The primary objective of this study is to assess the effect of early and rapid treprostinil
therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV)
function and reverse RV remodeling in participants with pulmonary arterial hypertension
IMPAHCT: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial is a Phase 2b/Phase
3 study to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in
patients with Pulmonary Arterial Hypertension (PAH). The Phase 2b part of the study will
assess three doses to establish an optimal dose for the Phase 3 part of the study. The Phase
2b primary endpoint will be the placebo corrected change in pulmonary vascular resistance
(PVR). The Phase 3 primary endpoint will be the placebo corrected change in 6-minute walk
distance (6MWD) after 24 weeks of treatment.
A Randomized, Placebo-Controlled, Double-blind, Dose Escalation Study to Assess Safety,
Efficacy and Pharmacokinetics of GMA301 Injection in Subjects with Pulmonary Arterial
The purpose of this study is to evaluate the effect of macitentan on hemodynamic measures at
Week 24 in pediatric populations.
The purpose of the study is to evaluate the change from baseline to 12 months after study
enrollment in the number of the following non-invasive risk criteria: World Health
Organization Functional Class (WHO/FC), 6-minute walk distance (6MWD), Brain Natriuretic
Peptide (BNP) or N-terminal pro-brain Natriuretic Peptide (NT-proBNP).